マーケットレポート詳細
体外診断(IVD)の世界市場：用途別、技術別2026年予測
In-Vitro Diagnostics/IVD Market by Product and Service (Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) End User (Hospitals) - Global Forecast to 2026
- 出版元：MarketsandMarkets
出版元について - 発行年：2022年3月
- 定価 ：Single User License(1名様ライセンス)US$4,950(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文415ページになります。
- 商品コード：MAM2893
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
体外診断(IVD)の世界市場規模は、今後2026年に1,131億ドルに増加する見通しです。2021年の同市場規模は982億ドルとみられ、2026年にかけて平均年成長率2.9％の漸増で推移すると予測されます。
レポートは体外診断(IVD)の世界市場について2026年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測（技術別市場、用途別市場、等）を中心に構成されています。また競合状況、主要企業情報（15社）、エコシステム分析、市場シェア分析などの分析も加味し、体外診断(IVD)市場の動向および今後成長性を詳細にレポートしています。
【レポート構成概要】
◆体外診断(IVD)の世界市場予測2019-2026年
・市場規模(US$)
◆製品/サービス別、市場-2026年
試薬/キット
機器
・全自動
・半自動
・その他
データ管理ソフトウェア
サービス
※(市場規模US$)
◆技術別、市場-2026年
イムノアッセイ/免疫化学
・ELISA (酵素結合免疫吸着測定法)
-化学発光イムノアッセイ
-蛍光イムノアッセイ
-比色イムノアッセイ
・ラジオイムノアッセイ
・迅速検査
・ウエスタンブロッティング
・ELISPOTアッセイ
臨床化学
・BMP(基本メタボリックパネル)
・肝パネル
・腎臓プロファイル
・脂質プロファイル
・甲状腺機能パネル
・電解質パネル
・特殊化学試験
分子診断
・ポリメラーゼ連鎖反応
・等温核酸増幅技術
・ハイブリダイゼーション
・DNAシーケンシング/次世代シーケンシング
・マイクロアレイ
・その他MDXテクノロジー
血液学
微生物学
凝固/止血
尿検査
その他技術
※(市場規模US$)
◆用途別、市場-2026年
・感染症
・糖尿病
・腫瘍学
・心臓病学
・薬物検査/ファーマコゲノミクス(PGx)
・HIV/AIDS
・自己免疫疾患
・腎臓学
・その他用途
※(市場規模US$)
◆エンドユーザー別、市場-2026年
病院ラボラトリーズ
臨床検査室
・大規模/リファレンスラボ
・中規模ラボラトリーズ
・小規模ラボラトリーズ
ポイントオブケア検査センター
患者自己診断
学術研究機関
その他エンドユーザー
※(市場規模US$)
◆主要国地域別市場-2026年
北米
・米国、カナダ
欧州
・ドイツ、フランス、英国
・イタリア、スペイン、ロシア
・その他欧州
アジア太平洋
・日本、中国、インド
・韓国、インドネシア
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・サウジアラビア
・その他中東
※地域別に各セグメント別の細分化データ掲載、詳細は目次参照
※国別に全セグメント別の細分化データ掲載、詳細は目次参照
◆市場分析
・市場ダイナミクス（ドライバー、障壁、機会、課題）
・ファイブフォース分析
・規制分析
・特許分析
・エコシステム分析
・COVID-19の影響
・ケーススタディ
・市場シェア分析
・競合状況
◆体外診断(IVD)の主要企業プロフィール動向
・ROCHE DIAGNOSTICS
・DANAHER CORPORATION
・ABBOTT LABORATORIES, INC.
・SIEMENS HEALTHINEERS
・シスメックス株式会社
・THERMO FISHER SCIENTIFIC, INC.
・BECTON, DICKINSON AND COMPANY
・BIOMÉRIEUX SA
・BIO-RAD LABORATORIES, INC.
・JOHNSON & JOHNSON
・AGILENT TECHNOLOGIES, INC.
・QIAGEN N.V.
・QUIDEL CORPORATION
・DIASORIN S.P.A.
・ILLUMINA, INC.
（その他企業）
・ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC
・PERKINELMER INC.
・CHEMBIO DIAGNOSTICS, INC.
・HOLOGIC, INC.
・SURMODICS, INC.
・SPEEDX PTY. LTD.
・GENSPEED BIOTECH GMBH
・ACCELERATE DIAGNOSTICS, INC.
・MERCK KGAA
・CARIS LIFE SCIENCES, INC.
（全415頁）
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1 INTRODUCTION 42
1.1 OBJECTIVES OF THE STUDY 42
1.2 MARKET DEFINITION 42
1.2.1 INCLUSIONS AND EXCLUSIONS 42
1.3 MARKET SCOPE 43
・ FIGURE 1 IN VITRO DIAGNOSTICS MARKET SEGMENTATION 43
・ FIGURE 2 IN VITRO DIAGNOSTICS MARKET, BY GEOGRAPHY 44
1.4 YEARS CONSIDERED FOR THE STUDY 44
1.5 CURRENCY 45
・ TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 45
1.6 LIMITATIONS 45
1.7 STAKEHOLDERS 45
1.8 SUMMARY OF CHANGES 45
2 RESEARCH METHODOLOGY 47
2.1 RESEARCH APPROACH 47
・ FIGURE 3 RESEARCH DESIGN 47
2.1.1 SECONDARY RESEARCH 48
2.1.1.1 KEY DATA FROM SECONDARY SOURCES 49
2.1.2 PRIMARY RESEARCH 49
2.1.3 PRIMARY SOURCES 49
・ FIGURE 4 KEY DATA FROM PRIMARY SOURCES 50
・ FIGURE 5 KEY INDUSTRY INSIGHTS 51
・ FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 51
・ FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 52
・ FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION 52
2.2 MARKET SIZE ESTIMATION 53
・ FIGURE 10 REVENUE SHARE ANALYSIS ILLUSTRATION: ROCHE DIAGNOSTICS (2020) 54
・ FIGURE 11 SUPPLY-SIDE ANALYSIS: IN VITRO DIAGNOSTICS MARKET (2020) 54
・ FIGURE 13 CAGR PROJECTIONS FROM THE ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF THE IVD INDUSTRY (2021-2026) 57
・ FIGURE 14 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF THE IN VITRO DIAGNOSTICS MARKET 58
2.3 DATA TRIANGULATION APPROACH 59
2.4 MARKET SHARE ESTIMATION 60
2.5 ASSUMPTIONS FOR THE STUDY 60
2.6 LIMITATIONS 60
2.6.1 METHODOLOGY-RELATED LIMITATIONS 60
2.6.2 SCOPE-RELATED LIMITATIONS 61
2.7 RISK ASSESSMENT 61
・ TABLE 2 RISK ASSESSMENT: IN VITRO DIAGNOSTICS MARKET 61
3 EXECUTIVE SUMMARY 62
4 PREMIUM INSIGHTS 66
4.1 IN VITRO DIAGNOSTICS MARKET OVERVIEW 66
4.2 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2020) 67
4.3 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 68
4.4 GEOGRAPHIC MIX: IN VITRO DIAGNOSTICS MARKET 68
4.5 IN VITRO DIAGNOSTICS MARKET: DEVELOPED VS. DEVELOPING MARKETS 69
5 MARKET OVERVIEW 70
5.1 INTRODUCTION 70
5.2 MARKET DYNAMICS 70
・ FIGURE 25 IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 70
5.2.1 DRIVERS 71
5.2.1.1 RISING GERIATRIC POPULATION AND SUBSEQUENT GROWTH IN THE PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES 71
・ TABLE 3 ESTIMATED INCREASE IN THE GERIATRIC POPULATION, BY REGION (2019–2050) 71
・ FIGURE 26 CHINA: NUMBER OF PEOPLE WITH DIABETES MELLITUS, 2000–2045 (IN MILLIONS) 72
5.2.1.2 SHIFT FROM CENTRALIZED TO POINT-OF-CARE TESTING 72
5.2.1.3 GROWING AWARENESS AND INITIATIVES TO INCREASE HEALTHCARE ACCESSIBILITY IN DEVELOPING COUNTRIES 72
5.2.1.4 CHANGING TECHNOLOGICAL LANDSCAPE 73
・ TABLE 4 IN VITRO DIAGNOSTICS MARKET: RECENT PRODUCT LAUNCHES 73
5.2.2 RESTRAINTS 74
5.2.2.1 UNFAVORABLE REIMBURSEMENT SCENARIO 74
5.2.3 OPPORTUNITIES 74
5.2.3.1 DEVELOPMENT OF DISEASE-SPECIFIC BIOMARKERS AND TESTS 74
・ TABLE 5 CANCER BIOMARKERS AND USES IN CLINICAL PRACTICE 74
5.2.3.2 GROWING SIGNIFICANCE OF COMPANION DIAGNOSTICS 75
5.2.3.3 GROWTH OPPORTUNITIES IN EMERGING COUNTRIES 75
・ FIGURE 27 ANNUAL PER CAPITA HEALTH EXPENDITURE IN DEVELOPING COUNTRIES, 2019 (USD MILLION) 76
5.2.4 CHALLENGES 76
5.2.4.1 CHANGING REGULATORY LANDSCAPE IN THE EU 76
・ FIGURE 28 IVDR: KEY AREAS OF IMPACT 77
5.2.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 77
6 INDUSTRY INSIGHTS 78
6.1 INDUSTRY TRENDS 78
6.1.1 AUTOMATION OF CLINICAL LABORATORY TECHNIQUES 78
6.1.2 MICROFLUIDICS-BASED POC AND LAB-ON-A-CHIP DIAGNOSTIC DEVICES FOR LABORATORY TESTING 78
6.1.3 GROWING NUMBER OF REAGENT RENTAL AGREEMENTS 79
6.2 PORTER’S FIVE FORCES ANALYSIS 79
・ TABLE 6 PORTER’S FIVE FORCES ANALYSIS: IN VITRO DIAGNOSTICS MARKET 79
6.2.1 INTENSITY OF COMPETITIVE RIVALRY 79
6.2.2 BARGAINING POWER OF SUPPLIERS 79
6.2.3 BARGAINING POWER OF BUYERS 80
6.2.4 THREAT OF NEW ENTRANTS 80
6.2.5 THREAT FROM SUBSTITUTES 80
6.3 REGULATORY ANALYSIS 80
6.3.1 US 80
・ TABLE 7 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 80
・ FIGURE 29 US: REGULATORY PROCESS FOR IVD DEVICES 81
6.3.2 CANADA 82
・ FIGURE 30 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA 82
6.3.3 EUROPE 83
・ TABLE 8 EUROPE: CLASSIFICATION OF IVD DEVICES 83
・ FIGURE 31 EUROPE: IVDR TIMELINE 83
6.3.4 JAPAN 84
・ FIGURE 32 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN 84
・ TABLE 9 JAPAN: CLASSIFICATION OF IVD REAGENTS 84
・ TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85
6.3.5 CHINA 85
・ TABLE 11 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85
6.3.6 INDIA 85
・ FIGURE 33 INDIA: REGULATORY PROCESS FOR IVD DEVICES 86
6.3.7 INDONESIA 86
・ TABLE 12 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES 87
6.3.8 RUSSIA 87
・ TABLE 13 RUSSIA: CLASSIFICATION OF IVD DEVICES 87
6.3.9 SAUDI ARABIA 88
・ TABLE 14 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 88
6.3.10 MEXICO 88
・ FIGURE 34 MEXICO: REGULATORY PROCESS FOR IVD DEVICES 88
・ TABLE 15 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 89
6.3.11 BRAZIL 89
・ FIGURE 35 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 90
6.3.12 SOUTH KOREA 90
・ TABLE 16 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 90
6.4 PATENT ANALYSIS 91
・ FIGURE 36 TOP PATENT OWNERS AND APPLICANTS: IN VITRO DIAGNOSTICS MARKET (JANUARY 2011–DECEMBER 2021) 91
・ FIGURE 37 PATENT ANALYSIS: IN VITRO DIAGNOSTICS MARKET
(JANUARY 2011–DECEMBER 2021) 92
6.5 TRADE ANALYSIS 92
6.5.1 TRADE ANALYSIS FOR DIAGNOSTICS AND LABORATORY REAGENTS 92
・ TABLE 17 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2016–2020 (USD MILLION) 92
・ TABLE 18 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2016–2020 (TONS) 93
6.6 ECOSYSTEM ANALYSIS 93
・ FIGURE 38 ECOSYSTEM ANALYSIS: IN VITRO DIAGNOSTICS MARKET 93
6.7 VALUE CHAIN ANALYSIS 94
・ FIGURE 39 VALUE CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET 94
6.8 SUPPLY CHAIN ANALYSIS 95
・ FIGURE 40 SUPPLY CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET 95
6.9 COVID-19 IMPACT ANALYSIS 96
6.9.1 COVID-19 HEALTH ASSESSMENT 96
6.9.2 COVID-19 ECONOMIC ASSESSMENT 96
6.9.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 96
・ FIGURE 41 CRITERIA IMPACTING THE GLOBAL ECONOMY 97
6.9.4 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE IN VITRO DIAGNOSTICS MARKET 98
・ FIGURE 42 COVID-19 IMPACT ON GLOBAL IN VITRO DIAGNOSTICS MARKET 98
・ FIGURE 43 ROCHE DIAGNOSTICS: IMPACT OF COVID-19 99
・ FIGURE 44 ABBOTT LABORATORIES, INC.: IMPACT OF COVID-19 99
6.10 PRICING ANALYSIS 100
・ TABLE 19 AVERAGE SELLING PRICE (USD): IMMUNOASSAY ANALYZERS 100
・ TABLE 20 AVERAGE SELLING PRICE (USD): LATERAL FLOW ANALYZERS 100
・ TABLE 21 AVERAGE SELLING PRICE (USD): MOLECULAR DIAGNOSTICS 100
6.11 TECHNOLOGY ANALYSIS 101
6.11.1 KEY TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET 101
6.11.2 ADJACENT TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET 102
6.12 ADJACENT MARKET ANALYSIS 102
・ FIGURE 45 MICROFLUIDICS MARKET: MARKET OVERVIEW 103
6.13 CASE STUDY 104
・ FIGURE 46 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA 104
7 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 105
7.1 INTRODUCTION
・ TABLE 22.. IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)
7.2 REAGENTS & KITS
7.2.1 TECHNOLOGICAL ADVANCES LIKE RAPID DIAGNOSTICS ARE EXPECTED TO BOOST THE GROWTH OF THIS SEGMENT
・ TABLE 23. IVD REAGENTS & KITS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 24............ IVD REAGENTS & KITS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)
7.3 INSTRUMENTS
・ TABLE 25.... IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
・ TABLE 26..... IVD INSTRUMENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 27 IVD INSTRUMENTS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
7.3.1 FULLY AUTOMATED INSTRUMENTS
7.3.1.1 RISING INCIDENCE OF VARIOUS DISEASES AND THE INCREASING NEED TO PROCESS HEAVY SAMPLE LOAD TO DRIVE THE MARKET GROWTH
・ TABLE 28.......... FULLY AUTOMATED IVD INSTRUMENTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
7.3.2 SEMI-AUTOMATED INSTRUMENTS
7.3.2.1 COMPACT DESIGN AND COST-EFFECTIVENESS OVER AUTOMATED ANALYZERS ARE EXPECTED TO INCREASE THE MARKET GROWTH OF THIS SEGMENT
・ TABLE 29........... SEMI-AUTOMATED IVD INSTRUMENTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
7.3.3 OTHER INSTRUMENTS.. 112
・ TABLE 30............ OTHER IVD INSTRUMENTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
7.4 DATA MANAGEMENT SOFTWARE
7.4.1 NEED FOR LABORATORY AUTOMATION DRIVES MARKET GROWTH
・ TABLE 31............. KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE IN THE MARKET
・ TABLE 32 IVD DATA MANAGEMENT SOFTWARE MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
・ TABLE 33............. IVD DATA MANAGEMENT SOFTWARE MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)
7.5 SERVICES
7.5.1 GROWING COMPETITIVENESS AND THE INCREASING NEED TO OFFER VALUE-ADDED SERVICES TO BOOST THE MARKET GROWTH
・ TABLE 34.... IVD SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 35...... IVD SERVICES MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
8.... IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
・ TABLE 36 IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
8.2 IMMUNOASSAY/IMMUNOCHEMISTRY
・ TABLE 37........... IMMUNOASSAY/IMMUNOCHEMISTRY ANALYZERS AVAILABLE
IN THE MARKET
・ TABLE 38 IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 39 IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY TYPE,
2019–2026 (USD MILLION)
8.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS
・ TABLE 40................. ELISA ANALYZERS AVAILABLE IN THE MARKET
・ TABLE 41.. ELISA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
・ TABLE 42........ ELISA MARKET, BY TYPE, 2019–2026 (USD MILLION)
8.2.1.1 CHEMILUMINESCENCE IMMUNOASSAYS
8.2.1.1.1 CLIAS HOLD THE LARGEST SHARE OF THE ELISA MARKET
・ TABLE 43............ CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN THE MARKET
・ TABLE 44....... CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
8.2.1.2 FLUORESCENCE IMMUNOASSAYS
8.2.1.2.1 RAPID PROCESSING, HIGH SENSITIVITY, AND LOW COST HAVE DRIVEN THE ADOPTION OF FIAS
・ TABLE 45... FLUORESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN THE MARKET
・ TABLE 46.. FLUORESCENCE IMMUNOASSAYS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
8.2.1.3 COLORIMETRIC IMMUNOASSAYS
8.2.1.3.1 DESPITE WIDESPREAD USE, DEMAND FOR COLORIMETRIC IMMUNOASSAYS HAS DECLINED DUE TO LOW SENSITIVITY
・ TABLE 47.... COLORIMETRIC IMMUNOASSAY SYSTEMS AVAILABLE IN THE MARKET
・ TABLE 48... COLORIMETRIC IMMUNOASSAYS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
8.2.2 RADIOIMMUNOASSAYS.. 129
8.2.2.1 SMALL SAMPLE VOLUMES, RAPID PROCESSING TIMES OFFSET BY HIGH COST AND POTENTIAL HEALTH HAZARDS
・ TABLE 49...... RADIOIMMUNOASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.2.3 RAPID TESTS
8.2.3.1 COVID-19 PANDEMIC DROVE DEMAND FOR RAPID TESTS
・ TABLE 50........................ RAPID TESTS AVAILABLE IN THE MARKET
・ TABLE 51..... RAPID TESTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.2.4 WESTERN BLOTTING.. 131
8.2.4.1 WESTERN BLOTTING IS THE GOLD STANDARD FOR RESULT VALIDATION
・ TABLE 52.. WESTERN BLOTTING SYSTEMS AVAILABLE IN THE MARKET
・ TABLE 53... WESTERN BLOTTING MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.2.5 ENZYME-LINKED IMMUNOSPOT ASSAYS
8.2.5.1 HIGH SENSITIVITY, FUNCTIONALITY, AND ADAPTABILITY SUPPORT THE GROWTH OF ELISPOT
・ TABLE 54 ELISPOT ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 CLINICAL CHEMISTRY
・ TABLE 55...... CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES
・ TABLE 56........ CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES
・ TABLE 57......... BLOOD GAS ANALYZERS AVAILABLE IN THE MARKET
・ TABLE 58....... IVD MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY,
2019–2026 (USD MILLION)
・ TABLE 59 CLINICAL CHEMISTRY MARKET, BY TYPE, 2019–2026 (USD MILLION)
8.3.1 BASIC METABOLIC PANELS
8.3.1.1 BASIC METABOLIC PANELS HOLD THE LARGEST SHARE OF THE CLINICAL CHEMISTRY MARKET
・ TABLE 60........... BASIC METABOLIC PANELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
8.3.2 LIVER PANELS
8.3.2.1 GROWING LIVER DISEASE BURDEN AND ALCOHOL CONSUMPTION DRIVING MARKET GROWTH
・ TABLE 61... LIVER PANELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.3.3 RENAL PROFILES
8.3.3.1 RISING KIDNEY DISEASE PREVALENCE ENSURES DEMAND FOR RENAL PROFILES
・ TABLE 62 RENAL PROFILES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.3.4 LIPID PROFILES
8.3.4.1 GROWTH IN CVD CASELOAD SUPPORTS THE ADOPTION OF LIPID PANELS
・ TABLE 63.. LIPID PROFILES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.3.5 THYROID FUNCTION PANELS
8.3.5.1 RISING AWARENESS AND INCIDENCE OF THYROID DISEASES DRIVE THE MARKET
・ TABLE 64......... THYROID FUNCTION PANELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
8.3.6 ELECTROLYTE PANELS
8.3.6.1 FOCUS ON PREVENTIVE HEALTHCARE TO FAVOR THE MARKET FOR ELECTROLYTE PANELS
・ TABLE 65. ELECTROLYTE PANELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.3.7 SPECIALTY CHEMICAL TESTS
8.3.7.1 INCLUDES TESTS NOT PRESCRIBED REGULARLY, SUCH AS PROTEIN TESTS, DRUGS-OF-ABUSE TESTS, AND THERAPEUTIC DRUG MONITORING
・ TABLE 66......... SPECIALTY CHEMICAL TESTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
8.4 MOLECULAR DIAGNOSTICS
・ TABLE 67......... AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE IN THE MARKET
・ TABLE 68 IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY,
2019–2026 (USD MILLION)
・ TABLE 69..... MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)
8.4.1 POLYMERASE CHAIN REACTION
8.4.1.1 PCR DOMINATES THE MOLECULAR DIAGNOSTICS MARKET
・ TABLE 70................ PCR INSTRUMENTS AVAILABLE IN THE MARKET
・ TABLE 71.... PCR MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
8.4.2.1 GROWING POPULARITY OF INAAT AND NAAT FOR INFECTIOUS DISEASE DIAGNOSTICS TO SUPPORT MARKET GROWTH
・ TABLE 72.. INAAT MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.4.3 HYBRIDIZATION
8.4.3.1 ADVANCED IN HYBRIDIZATION AND AUTOMATION HAVE DRIVEN THE ADOPTION OF HYBRIDIZATION TECHNOLOGIES
・ TABLE 73.. HYBRIDIZATION MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.4.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
8.4.4.1 GROWING USE IN PERSONALIZED MEDICINE AND DECLINING COSTS
・ TABLE 74............... NGS INSTRUMENTS AVAILABLE IN THE MARKET
・ TABLE 75............ DNA SEQUENCING & NGS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)
8.4.5 MICROARRAYS
8.4.5.1 ADVANTAGES OF MICROARRAYS—HIGH THROUGHPUT, RESOLUTION, AND SENSITIVITY—DRIVE THEIR ADOPTION
・ TABLE 76.. MICROARRAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.4.6 OTHER MDX TECHNOLOGIES
・ TABLE 77 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 HEMATOLOGY
8.5.1 INCREASING ADOPTION OF AUTOMATED HEMATOLOGY ANALYZERS IS EXPECTED TO DRIVE THE MARKET GROWTH
・ TABLE 78....... HEMATOLOGY ANALYZERS AVAILABLE IN THE MARKET
・ TABLE 79 IVD MARKET FOR HEMATOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
8.6 MICROBIOLOGY
8.6.1 RISING PREVALENCE OF INFECTIOUS DISEASES WILL BOOST THE GROWTH OF THIS SEGMENT
・ TABLE 80. MICROBIOLOGY INSTRUMENTS AVAILABLE IN THE MARKET
・ TABLE 81..... IVD MARKET FOR MICROBIOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
8.7 COAGULATION & HEMOSTASIS
8.7.1 INCREASING NUMBER OF SURGERIES AND GROWING USE OF ANTICOAGULATION THERAPY WILL DRIVE THE MARKET GROWTH FOR THIS SEGMENT
・ TABLE 82...... COAGULATION ANALYZERS AVAILABLE IN THE MARKET
・ TABLE 83.......... POINT-OF-CARE/SELF-MONITORING COAGULATION ANALYZERS AVAILABLE IN THE MARKET
・ TABLE 84......... IVD MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY,
2019–2026 (USD MILLION)
8.8 URINALYSIS
8.8.1 RISING PREVALENCE OF DIABETES AND KIDNEY DISORDERS WILL HAVE A POSITIVE IMPACT ON THE GROWTH OF THIS SEGMENT
・ TABLE 85..... URINALYSIS INSTRUMENTS AVAILABLE IN THE MARKET
・ TABLE 86.. IVD MARKET FOR URINALYSIS, BY COUNTRY, 2019–2026 (USD MILLION)
8.9 OTHER TECHNOLOGIES
・ TABLE 87..... BLOOD GLUCOSE TESTING SYSTEMS AVAILABLE IN THE MARKET
・ TABLE 88.. TISSUE PROCESSORS, EMBEDDERS, MICROTOMES, AND STAINERS AVAILABLE IN THE MARKET
・ TABLE 89..... IVD MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,
2019–2026 (USD MILLION)
9.... IN VITRO DIAGNOSTICS MARKET, BY APPLICATION
9.1 INTRODUCTION
・ TABLE 90 IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
9.2 INFECTIOUS DISEASES
9.2.1 INFECTIOUS DISEASES ACCOUNTED FOR THE LARGEST MARKET
SHARE IN 2020
・ TABLE 91..... IVD MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,
2019–2026 (USD MILLION)
9.3 DIABETES
9.3.1 DIABETES PATIENTS REQUIRE CONSTANT MONITORING
・ TABLE 92... GLOBAL DIABETIC PATIENT POPULATION, 2019 VS. 2030 (MILLION)
・ TABLE 93..... IVD MARKET FOR DIABETES, BY COUNTRY, 2019–2026 (USD MILLION)
9.4 ONCOLOGY
9.4.1 ADVANCEMENTS IN MOLECULAR DIAGNOSTICS WILL AID THE EARLY DIAGNOSIS OF CANCER
・ TABLE 94... IVD MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
9.5 CARDIOLOGY
9.5.1 INCREASING DISEASE BURGEN OF CVD TO DRIVE THE MARKET GROWTH
・ TABLE 95. IVD MARKET FOR CARDIOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
9.6 DRUG TESTING/PHARMACOGENOMICS
9.6.1 INCREASING CONSUMPTION OF ILLICIT DRUGS WILL LEAD TO AN INCREASE IN TOXICOLOGY TESTING
・ TABLE 96.. IVD MARKET FOR DRUG TESTING/PHARMACOGENOMICS, BY COUNTRY, 2019–2026 (USD MILLION)
9.7 HIV/AIDS
9.7.1 HIGH PREVALENCE OF AIDS IS EXPECTED TO BOOST THE MARKET GROWTH
・ TABLE 97...... IVD MARKET FOR HIV/AIDS, BY COUNTRY, 2019–2026 (USD MILLION)
9.8 AUTOIMMUNE DISEASES
9.8.1 DEVELOPMENT OF NOVEL DISEASE-SPECIFIC BIOMARKERS WILL HAVE A POSITIVE IMPACT ON THE MARKET GROWTH
・ TABLE 98.. IVD MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY,
2019–2026 (USD MILLION)
9.9 NEPHROLOGY
9.9.1 INCREASING PREVALENCE OF CHRONIC KIDNEY DISEASES IS EXPECTED TO DRIVE THE MARKET GROWTH FOR THIS SEGMENT
・ TABLE 99 IVD MARKET FOR NEPHROLOGY, BY COUNTRY, 2019–2026 (USD MILLION)
9.10 OTHER APPLICATIONS
9.10.1 INCREASING DEMAND FOR SELF-MONITORING KITS IS LIKELY TO HAVE A POSITIVE IMPACT ON THE MARKET GROWTH.. 175
・ TABLE 100.... IVD MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2019–2026 (USD MILLION)
10 IN VITRO DIAGNOSTICS MARKET, BY END USER 177
10.1 INTRODUCTION 178
・ TABLE 101 IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 178
10.2 HOSPITAL LABORATORIES 178
10.2.1 GROWING PATIENT POPULATION AND REIMBURSEMENT POLICIES FOR DIAGNOSTIC TESTS WILL DRIVE THE MARKET GROWTH 178
・ TABLE 102 IVD MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY,
2019–2026 (USD MILLION) 179
10.3 CLINICAL LABORATORIES 179
・ TABLE 103 IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 180
・ TABLE 104 IVD MARKET FOR CLINICAL LABORATORIES, BY COUNTRY
2019–2026 (USD MILLION) 180
10.3.1 LARGE/REFERENCE LABORATORIES 181
10.3.1.1 RISING INFECTIOUS DISEASE BURDEN AND DEMAND FOR LARGER TESTING CAPACITIES WILL DRIVE THE GROWTH OF THIS SEGMENT 181
・ TABLE 105 LARGE/REFERENCE LABORATORIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 181
10.3.2 MEDIUM-SIZED LABORATORIES 182
10.3.2.1 INCREASING USE OF AUTOMATED INSTRUMENTS TO DRIVE MARKET GROWTH 182
・ TABLE 106 MEDIUM-SIZED LABORATORIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 182
10.3.3 SMALL LABORATORIES 182
10.3.3.1 INCREASING ADOPTION OF SEMI-AUTOMATED INSTRUMENTS AND LOW-END POINT-OF-CARE DEVICES WILL BOOST SEGMENT GROWTH 182
・ TABLE 107 SMALL LABORATORIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 183
10.4 POINT-OF-CARE TESTING CENTERS 183
10.4.1 GROWING USE OF POC DEVICES IN HOSPITALS AND CLINICAL LABORATORIES IS EXPECTED TO PROPEL THE GROWTH OF THIS SEGMENT 183
・ TABLE 108 IVD MARKET FOR POINT-OF-CARE TESTING CENTERS, BY COUNTRY,
2019–2026 (USD MILLION) 184
10.5 PATIENTS 184
10.5.1 INCREASING ADOPTION OF PATIENT SELF-TESTING KITS TO DRIVE THE MARKET GROWTH 184
・ TABLE 109 IVD MARKET FOR PATIENTS, BY COUNTRY, 2019–2026 (USD MILLION) 185
10.6 ACADEMIC INSTITUTES 185
10.6.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT SUPPORTS MARKET GROWTH 185
・ TABLE 110 IVD MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY,
2019–2026 (USD MILLION) 186
10.7 OTHER END USERS 186
・ TABLE 111 IVD MARKET FOR OTHER END USERS, BY COUNTRY,
2019–2026 (USD MILLION) 187
11 IN VITRO DIAGNOSTICS MARKET, BY REGION 188
11.1 INTRODUCTION 189
・ TABLE 112 IVD MARKET, BY REGION, 2019–2026 (USD MILLION) 189
11.2 NORTH AMERICA 189
・ FIGURE 47 NORTH AMERICA: IVD MARKET SNAPSHOT 190
・ TABLE 113 NORTH AMERICA: IVD MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 190
・ TABLE 114 NORTH AMERICA: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 191
・ TABLE 115 NORTH AMERICA: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 191
・ TABLE 116 NORTH AMERICA: IVD MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 191
・ TABLE 117 NORTH AMERICA: IVD MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 192
・ TABLE 118 NORTH AMERICA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 192
・ TABLE 119 NORTH AMERICA: IVD MARKET FOR CLINICAL LABORATORIES,
BY TYPE, 2019–2026 (USD MILLION) 193
11.2.1 US 193
11.2.1.1 THE US DOMINATES THE NORTH AMERICAN MARKET 193
・ TABLE 120 US: MACROECONOMIC INDICATORS 194
・ TABLE 121 US: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 194
・ TABLE 122 US: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 194
・ TABLE 123 US: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 195
・ TABLE 124 US: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 195
・ TABLE 125 US: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 196
・ TABLE 126 US: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 196
11.2.2 CANADA 196
11.2.2.1 INCREASING PREVALENCE OF CHRONIC ILLNESS AND IMPLEMENTATION OF FAVORABLE GOVERNMENT INITIATIVES DRIVE THE MARKET IN CANADA 196
・ TABLE 127 CANADA: ESTIMATED PREVALENCE OF DIABETES 197
・ TABLE 128 CANADA: MACROECONOMIC INDICATORS 197
・ TABLE 129 CANADA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 198
・ TABLE 130 CANADA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 198
・ TABLE 131 CANADA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 198
・ TABLE 132 CANADA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 199
・ TABLE 133 CANADA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 199
・ TABLE 134 CANADA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 200
11.3 EUROPE 200
・ TABLE 135 EUROPE: IVD MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 201
・ TABLE 136 EUROPE: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 201
・ TABLE 137 EUROPE: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 202
・ TABLE 138 EUROPE: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 202
・ TABLE 139 EUROPE: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 203
・ TABLE 140 EUROPE: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 203
・ TABLE 141 EUROPE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 203
11.3.1 GERMANY 204
11.3.1.1 INCREASING HEALTHCARE EXPENDITURE TO DRIVE THE MARKET GROWTH IN GERMANY 204
・ TABLE 142 GERMANY: MACROECONOMIC INDICATORS 204
・ TABLE 143 GERMANY: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 204
・ TABLE 144 GERMANY: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 205
・ TABLE 145 GERMANY: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 205
・ TABLE 146 GERMANY: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 206
・ TABLE 147 GERMANY: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 206
・ TABLE 148 GERMANY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 207
11.3.2 FRANCE 207
11.3.2.1 RISING R&D EXPENDITURE IN FRANCE TO DRIVE MARKET GROWTH 207
・ TABLE 149 FRANCE: MACROECONOMIC INDICATORS 207
・ TABLE 150 FRANCE: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 208
・ TABLE 151 FRANCE: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 208
・ TABLE 152 FRANCE: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 208
・ TABLE 153 FRANCE: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 209
・ TABLE 154 FRANCE: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 209
・ TABLE 155 FRANCE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 210
11.3.3 UK 210
11.3.3.1 THE INCREASING NUMBER OF ACCREDITED DIAGNOSTIC LABORATORIES PROPELS MARKET GROWTH FOR IN VITRO DIAGNOSTICS IN THE UK 210
・ TABLE 156 UK: MACROECONOMIC INDICATORS 211
・ TABLE 157 UK: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 211
・ TABLE 158 UK: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 211
・ TABLE 159 UK: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 212
・ TABLE 160 UK: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 212
・ TABLE 161 UK: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 213
・ TABLE 162 UK: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 213
11.3.4 ITALY 213
11.3.4.1 ADOPTION OF ADVANCED DIAGNOSTIC TECHNOLOGIES TO DRIVE MARKET GROWTH IN ITALY 213
・ TABLE 163 ITALY: MACROECONOMIC INDICATORS 214
・ TABLE 164 ITALY: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 214
・ TABLE 165 ITALY: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 214
・ TABLE 166 ITALY: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 215
・ TABLE 167 ITALY: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 215
・ TABLE 168 ITALY: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 216
・ TABLE 169 ITALY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 216
11.3.5 SPAIN 216
11.3.5.1 GROWTH OF THE GERIATRIC POPULATION AND RISING DEMAND FOR TESTING SUPPORT THE MARKET IN SPAIN 216
・ TABLE 170 SPAIN: MACROECONOMIC INDICATORS 217
・ TABLE 171 SPAIN: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 217
・ TABLE 172 SPAIN: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 217
・ TABLE 173 SPAIN: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 218
・ TABLE 174 SPAIN: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 218
・ TABLE 175 SPAIN: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 219
・ TABLE 176 SPAIN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 219
11.3.6 RUSSIA 219
11.3.6.1 INCREASING ACCESS TO QUALITY HEALTHCARE WILL SUPPORT MARKET GROWTH IN RUSSIA 219
・ TABLE 177 RUSSIA: MACROECONOMIC INDICATORS 220
・ TABLE 178 RUSSIA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 220
・ TABLE 179 RUSSIA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 220
・ TABLE 180 RUSSIA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 221
・ TABLE 181 RUSSIA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 221
・ TABLE 182 RUSSIA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 222
・ TABLE 183 RUSSIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 222
11.3.7 REST OF EUROPE 222
・ TABLE 184 ROE: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 223
・ TABLE 185 ROE: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 223
・ TABLE 186 ROE: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 223
・ TABLE 187 ROE: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 224
・ TABLE 188 ROE: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 224
・ TABLE 189 ROE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 225
11.4 ASIA PACIFIC 225
・ FIGURE 48 ASIA PACIFIC: IVD MARKET SNAPSHOT 226
・ TABLE 190 ASIA PACIFIC: IVD MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 227
・ TABLE 191 ASIA PACIFIC: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 227
・ TABLE 192 ASIA PACIFIC: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 227
・ TABLE 193 ASIA PACIFIC: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 228
・ TABLE 194 ASIA PACIFIC: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 229
・ TABLE 195 ASIA PACIFIC: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 229
・ TABLE 196 ASIA PACIFIC: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 230
11.4.1 JAPAN 230
11.4.1.1 UNIVERSAL HEALTHCARE REIMBURSEMENT POLICY TO DRIVE MARKET
GROWTH IN JAPAN 230
・ TABLE 197 JAPAN: MACROECONOMIC INDICATORS 231
・ TABLE 198 JAPAN: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 231
・ TABLE 199 JAPAN: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 231
・ TABLE 200 JAPAN: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 232
・ TABLE 201 JAPAN: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 232
・ TABLE 202 JAPAN: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 233
・ TABLE 203 JAPAN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 233
11.4.2 CHINA 233
11.4.2.1 GROWING PUBLIC ACCESS TO MODERN HEALTHCARE AND THE OUTBREAK OF COVID-19 TO DRIVE MARKET GROWTH 233
・ TABLE 204 CHINA: MACROECONOMIC INDICATORS 234
・ TABLE 205 CHINA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 234
・ TABLE 206 CHINA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 234
・ TABLE 207 CHINA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 235
・ TABLE 208 CHINA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 235
・ TABLE 209 CHINA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 236
・ TABLE 210 CHINA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 236
11.4.3 INDIA 236
11.4.3.1 INCREASING PRIVATE & PUBLIC INVESTMENTS IN THE COUNTRY’S HEALTHCARE SYSTEM WILL DRIVE MARKET GROWTH 236
・ TABLE 211 INDIA: MACROECONOMIC INDICATORS 237
・ TABLE 212 INDIA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 237
・ TABLE 213 INDIA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 237
・ TABLE 214 INDIA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 238
・ TABLE 215 INDIA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 238
・ TABLE 216 INDIA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 239
・ TABLE 217 INDIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 239
11.4.4 SOUTH KOREA 239
11.4.4.1 INCREASED GERIATRIC POPULATION COUPLED WITH A PARALLEL INCREASE IN CHRONIC ILLNESSES TO DRIVE THE MARKET GROWTH 239
・ TABLE 218 SOUTH KOREA: MACROECONOMIC INDICATORS 240
・ TABLE 219 SOUTH KOREA: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 240
・ TABLE 220 SOUTH KOREA: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 240
・ TABLE 221 SOUTH KOREA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 241
・ TABLE 222 SOUTH KOREA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 241
・ TABLE 223 SOUTH KOREA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 242
・ TABLE 224 SOUTH KOREA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 242
11.4.5 INDONESIA 242
11.4.5.1 INCREASING INSURANCE PENETRATION AND RISING BURDEN OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH 242
・ TABLE 225 INDONESIA: MACROECONOMIC INDICATORS 243
・ TABLE 226 INDONESIA: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 243
・ TABLE 227 INDONESIA: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 243
・ TABLE 228 INDONESIA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 244
・ TABLE 229 INDONESIA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 244
・ TABLE 230 INDONESIA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 245
・ TABLE 231 INDONESIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 245
11.4.6 REST OF ASIA PACIFIC 245
・ TABLE 232 ROAPAC: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 246
・ TABLE 233 ROAPAC: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 246
・ TABLE 234 ROAPAC: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 246
・ TABLE 235 ROAPAC: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 247
・ TABLE 236 ROAPAC: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 247
・ TABLE 237 ROAPAC: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 248
11.5 LATIN AMERICA 248
・ TABLE 238 LATIN AMERICA: IVD MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 248
・ TABLE 239 LATIN AMERICA: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 249
・ TABLE 240 LATIN AMERICA: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 249
・ TABLE 241 LATIN AMERICA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 249
・ TABLE 242 LATIN AMERICA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 250
・ TABLE 243 LATIN AMERICA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 250
・ TABLE 244 LATIN AMERICA: IVD MARKET FOR CLINICAL LABORATORIES,
BY TYPE, 2019–2026 (USD MILLION) 251
11.5.1 BRAZIL 251
11.5.1.1 IMPROVING HEALTHCARE INFRASTRUCTURE IN BRAZIL TO DRIVE THE GROWTH OF THE IVD MARKET 251
・ TABLE 245 BRAZIL: MACROECONOMIC INDICATORS 252
・ TABLE 246 BRAZIL: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 252
・ TABLE 247 BRAZIL: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 252
・ TABLE 248 BRAZIL: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 253
・ TABLE 249 BRAZIL: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 253
・ TABLE 250 BRAZIL: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 254
・ TABLE 251 BRAZIL: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 254
11.5.2 MEXICO 254
11.5.2.1 IMPROVING ACCESSIBILITY AND AFFORDABILITY OF HEALTHCARE SERVICES TO DRIVE MARKET GROWTH FOR IN VITRO DIAGNOSTICS 254
・ TABLE 252 MEXICO: MACROECONOMIC INDICATORS 255
・ TABLE 253 MEXICO: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 255
・ TABLE 254 MEXICO: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 255
・ TABLE 255 MEXICO: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 256
・ TABLE 256 MEXICO: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 256
・ TABLE 257 MEXICO: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 257
・ TABLE 258 MEXICO: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 257
11.5.3 REST OF LATIN AMERICA 257
・ TABLE 259 ROLA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 258
・ TABLE 260 ROLA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 258
・ TABLE 261 ROLA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 258
・ TABLE 262 ROLA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 259
・ TABLE 263 ROLA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 259
・ TABLE 264 ROLA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 260
11.6 MIDDLE EAST & AFRICA 260
・ TABLE 265 MIDDLE EAST & AFRICA: IVD MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 260
・ TABLE 266 MIDDLE EAST & AFRICA: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 261
・ TABLE 267 MIDDLE EAST & AFRICA: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 261
・ TABLE 268 MIDDLE EAST & AFRICA: IVD MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 261
・ TABLE 269 MIDDLE EAST & AFRICA: IVD MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 262
・ TABLE 270 MIDDLE EAST & AFRICA: IVD MARKET, BY END USER,
2019–2026 (USD MILLION) 262
・ TABLE 271 MIDDLE EAST & AFRICA: IVD MARKET FOR CLINICAL LABORATORIES,
BY TYPE, 2019–2026 (USD MILLION) 263
11.6.1 SAUDI ARABIA 263
11.6.1.1 HIGH INCIDENCE OF LIFESTYLE DISEASES COUPLED WITH INCREASING HEALTHCARE BUDGET IS TO DRIVE MARKET GROWTH 263
・ TABLE 272 SAUDI ARABIA: MACROECONOMIC INDICATORS 263
・ TABLE 273 SAUDI ARABIA: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 264
・ TABLE 274 SAUDI ARABIA: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 264
・ TABLE 275 SAUDI ARABIA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 264
・ TABLE 276 SAUDI ARABIA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 265
・ TABLE 277 SAUDI ARABIA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 265
・ TABLE 278 SAUDI ARABIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 266
11.6.2 REST OF MIDDLE EAST & AFRICA 266
・ TABLE 279 ROMEA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 266
・ TABLE 280 ROMEA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 267
・ TABLE 281 ROMEA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 267
・ TABLE 282 ROMEA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 268
・ TABLE 283 ROMEA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 268
・ TABLE 284 ROMEA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 269
12 COMPETITIVE LANDSCAPE 270
12.1 OVERVIEW 270
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 270
12.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE IN VITRO DIAGNOSTICS MARKET 272
12.4 MARKET SHARE ANALYSIS 273
・ TABLE 285 IN VITRO DIAGNOSTICS MARKET: DEGREE OF COMPETITION 273
12.4.1 MARKET SHARE ANALYSIS, BY TECHNOLOGY 275
12.4.1.1 CLINICAL CHEMISTRY 275
・ FIGURE 52 CLINICAL CHEMISTRY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 275
12.4.1.2 IMMUNOCHEMISTRY/IMMUNOASSAY ANALYZERS 275
・ FIGURE 53 IMMUNOASSAYS MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 275
12.4.1.3 MICROBIOLOGY 276
・ FIGURE 54 MICROBIOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 276
12.4.1.4 MOLECULAR DIAGNOSTICS 276
・ FIGURE 55 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 276
12.4.1.5 HEMATOLOGY 277
・ FIGURE 56 HEMATOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 277
12.4.1.6 COAGULATION & HEMOSTASIS 277
・ FIGURE 57 COAGULATION & HEMOSTASIS MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 277
12.4.1.7 URINALYSIS 278
・ FIGURE 58 URINALYSIS MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 278
12.5 R&D ASSESSMENT OF KEY PLAYERS 278
12.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS 279
・ FIGURE 59 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC REVENUE MIX 279
12.7 COMPANY EVALUATION QUADRANT 280
12.7.1 STARS 280
12.7.2 PERVASIVE PLAYERS 280
12.7.3 EMERGING LEADERS 280
12.7.4 PARTICIPANTS 280
・ FIGURE 60 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX, 2020 281
12.8 COMPETITIVE LEADERSHIP MAPPING FOR SMES & START-UPS 282
12.8.1 PROGRESSIVE COMPANIES 282
12.8.2 DYNAMIC COMPANIES 282
12.8.3 STARTING BLOCKS 282
12.8.4 RESPONSIVE COMPANIES 282
・ FIGURE 61 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR SMES & START-UPS 283
12.9 COMPETITIVE BENCHMARKING 284
・ TABLE 286 OVERALL COMPANY FOOTPRINT 284
・ TABLE 287 COMPANY FOOTPRINT: BY PRODUCT AND SERVICE 285
・ TABLE 288 COMPANY FOOTPRINT: BY TECHNOLOGY 286
・ TABLE 289 COMPANY FOOTPRINT: BY APPLICATION 287
・ TABLE 290 COMPANY FOOTPRINT: BY END USER 288
12.10 COMPETITIVE SCENARIO 290
12.10.1 PRODUCT LAUNCHES & APPROVALS 290
・ TABLE 291 PRODUCT LAUNCHES & APPROVALS, 2020–2022 290
12.10.2 DEALS 291
・ TABLE 292 DEALS, 2021 291
12.10.3 OTHER DEVELOPMENTS 291
・ TABLE 293 OTHER DEVELOPMENTS, 2021 291
13 COMPANY PROFILES 292
(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW)*
13.1 KEY PLAYERS 292
13.1.1 ROCHE DIAGNOSTICS 292
・ TABLE 294 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW 292
・ FIGURE 62 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2020) 293
・ TABLE 295 PRODUCT LAUNCHES AND APPROVALS 297
・ TABLE 296 DEALS 300
13.1.2 DANAHER CORPORATION 303
・ TABLE 297 DANAHER CORPORATION: BUSINESS OVERVIEW 303
・ FIGURE 63 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 304
・ TABLE 298 DEALS 308
13.1.3 ABBOTT LABORATORIES, INC. 310
・ TABLE 299 ABBOTT LABORATORIES: BUSINESS OVERVIEW 310
・ FIGURE 64 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020) 311
・ TABLE 300 PRODUCT LAUNCHES AND APPROVALS 313
・ TABLE 301 DEALS 315
13.1.4 SIEMENS HEALTHINEERS 317
・ TABLE 302 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW 317
・ FIGURE 65 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2021) 318
・ TABLE 303 PRODUCT LAUNCHES AND APPROVALS 321
・ TABLE 304 DEALS 321
・ TABLE 305 OTHER DEVELOPMENTS 322
13.1.5 SYSMEX CORPORATION 324
・ TABLE 306 SYSMEX CORPORATION: BUSINESS OVERVIEW 324
・ FIGURE 66 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020) 325
・ TABLE 307 PRODUCT LAUNCHES AND APPROVALS 327
・ TABLE 308 DEALS 329
・ TABLE 309 OTHER DEVELOPMENTS 330
13.1.6 THERMO FISHER SCIENTIFIC, INC. 332
・ TABLE 310 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 332
・ FIGURE 67 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020) 333
・ TABLE 311 PRODUCT LAUNCHES AND APPROVALS 339
・ TABLE 312 DEALS 342
・ TABLE 313 OTHER DEVELOPMENTS 344
13.1.7 BECTON, DICKINSON AND COMPANY 345
・ TABLE 314 BD: BUSINESS OVERVIEW 345
・ FIGURE 68 BD: COMPANY SNAPSHOT (2021) 346
・ TABLE 315 PRODUCT LAUNCHES AND APPROVALS 349
・ TABLE 316 DEALS 350
13.1.8 BIOMÉRIEUX SA 351
・ TABLE 317 BIOMÉRIEUX SA: BUSINESS OVERVIEW 351
・ FIGURE 69 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020) 352
・ TABLE 318 PRODUCT LAUNCHES AND APPROVALS 355
・ TABLE 319 DEALS 356
13.1.9 BIO-RAD LABORATORIES, INC. 357
・ TABLE 320 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 357
・ FIGURE 70 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020) 358
・ TABLE 321 PRODUCT LAUNCHES AND APPROVALS 363
・ TABLE 322 DEALS 363
13.1.10 JOHNSON & JOHNSON 365
・ TABLE 323 JOHNSON & JOHNSON: BUSINESS OVERVIEW 365
・ FIGURE 71 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2020) 365
13.1.11 AGILENT TECHNOLOGIES, INC. 367
・ TABLE 324 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 367
・ FIGURE 72 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020) 368
・ TABLE 325 PRODUCT LAUNCHES AND APPROVALS 371
・ TABLE 326 DEALS 372
13.1.12 QIAGEN N.V. 374
・ TABLE 327 QIAGEN N.V.: BUSINESS OVERVIEW 374
・ FIGURE 73 QIAGEN N.V.: COMPANY SNAPSHOT (2020) 374
・ TABLE 328 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS 378
・ TABLE 329 DEALS 380
・ TABLE 330 OTHER DEVELOPMENTS 381
13.1.13 QUIDEL CORPORATION 382
・ TABLE 331 QUIDEL CORPORATION: BUSINESS OVERVIEW 382
・ FIGURE 74 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020) 382
・ TABLE 332 PRODUCT LAUNCHES AND APPROVALS 383
・ TABLE 333 DEALS 384
・ TABLE 334 OTHER DEVELOPMENTS 385
13.1.14 DIASORIN S.P.A. 386
・ TABLE 335 DIASORIN S.P.A.: BUSINESS OVERVIEW 386
・ FIGURE 75 DIASORIN S.P.A.: COMPANY SNAPSHOT (2020) 387
・ TABLE 336 PRODUCT LAUNCHES AND APPROVALS 389
・ TABLE 337 DEALS 392
・ TABLE 338 OTHER DEVELOPMENTS 393
13.1.15 ILLUMINA, INC. 394
・ TABLE 339 ILLUMINA, INC.: BUSINESS OVERVIEW 394
・ FIGURE 76 ILLUMINA, INC.: COMPANY SNAPSHOT (2020) 394
・ TABLE 340 PRODUCT REGISTRATIONS, LAUNCHES, AND APPROVALS 396
・ TABLE 341 DEALS 397
・ TABLE 342 OTHER DEVELOPMENTS 398
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
13.2 OTHER PLAYERS 399
13.2.1 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC 399
・ TABLE 343 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: BUSINESS OVERVIEW 399
・ FIGURE 77 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2020) 400
13.2.2 PERKINELMER INC. 402
・ TABLE 344 PERKINELMER, INC.: BUSINESS OVERVIEW 402
・ FIGURE 78 PERKINELMER, INC.: COMPANY SNAPSHOT (2020) 403
13.2.3 CHEMBIO DIAGNOSTICS, INC. 405
・ TABLE 345 CHEMBIO DIAGNOSTICS, INC.: BUSINESS OVERVIEW 405
・ FIGURE 79 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2020) 405
13.2.4 HOLOGIC, INC. 407
・ TABLE 346 HOLOGIC, INC.: BUSINESS OVERVIEW 407
・ FIGURE 80 HOLOGIC, INC.: COMPANY SNAPSHOT (2021) 407
13.2.5 SURMODICS, INC. 409
・ TABLE 347 SURMODICS, INC.: BUSINESS OVERVIEW 409
・ FIGURE 81 SURMODICS, INC.: COMPANY SNAPSHOT (2020) 409
13.2.6 SPEEDX PTY. LTD. 411
13.2.7 GENSPEED BIOTECH GMBH 412
13.2.8 ACCELERATE DIAGNOSTICS, INC. 413
13.2.9 MERCK KGAA 413
13.2.10 CARIS LIFE SCIENCES, INC. 416
14 APPENDIX 417